Sandbox bcce8

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 10: Line 10:
== Relevance ==
== Relevance ==
-
Deficiencies in the human form of &beta;-glucuronidase (<scene name='59/596447/Human_bglucuronidase/1'>TextToBeDisplayed</scene>) is associated with a disease known as Sly Syndrome (AKA Mucopolysaccharidosis VII -- MPS VII). This disease is characterized by mental retardation, short stature, macrocephaly, and enlarged joints. As is commonly seen with genetic disorders, patients with this disease present a spectrum of symptom severity, but the disease is always ultimately fatal.
+
Deficiencies in the human form of &beta;-glucuronidase (<scene name='59/596447/Human_bglucuronidase/1'>overall structure</scene>) is associated with a disease known as Sly Syndrome (AKA Mucopolysaccharidosis VII -- MPS VII). This disease is characterized by mental retardation, short stature, macrocephaly, and enlarged joints. As is commonly seen with genetic disorders, patients with this disease present a spectrum of symptom severity, but the disease is always ultimately fatal.
-
The ''E. coli'' form of &beta;-glucuronidase (<scene name='59/596447/E_coli_b-glucuronidase/1'>ribbon diagram</scene>) is associated with the side effects seen with administration of the cancer chemotherapy drug CPT-11. This drug gets converted to SN38, a topoisomerase inhibitor, by the liver. The body adds a glucuronide group to this molecule (now SN38-G) to mark it for elimination, which partially occurs through the intestine. Once in the intestine, bacterial &beta;-glucuronidase cleaves the glucuronide from the SN38-G, releasing the SN38 into the intestinal lumen. The released SN38 prevents cell division, compromising the epithelial lining of the intestines, a painful and dangerous side-effect of CPT-11 administration.
+
The ''E. coli'' form of &beta;-glucuronidase (<scene name='59/596447/E_coli_b-glucuronidase/1'>overall structure</scene>) is associated with the side effects seen with administration of the cancer chemotherapy drug CPT-11. This drug gets converted to SN38, a topoisomerase inhibitor, by the liver. The body adds a glucuronide group to this molecule (now SN38-G) to mark it for elimination, which partially occurs through the intestine. Once in the intestine, bacterial &beta;-glucuronidase cleaves the glucuronide from the SN38-G, releasing the SN38 into the intestinal lumen. The released SN38 prevents cell division, compromising the epithelial lining of the intestines, a painful and dangerous side-effect of CPT-11 administration.
Selective inhibition of bacterial &beta;-glucuronidase is desired to alleviate this side-effect of CPT-11 treatment, hopefully without inhibiting the human form of the enzyme.
Selective inhibition of bacterial &beta;-glucuronidase is desired to alleviate this side-effect of CPT-11 treatment, hopefully without inhibiting the human form of the enzyme.

Revision as of 15:22, 6 August 2014

β-Glucuronidase

Ribbon diagram of human β-glucuronidase

Drag the structure with the mouse to rotate

References

Personal tools